source
- Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent winA Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…
- ARPA-H launches Surpass program to speed and broaden clinical trialsThe U.S. Department of Health and Human Services announced a new initiative called Surpass, aimed at removing obstacles that slow clinical development and changing how trials are designed and run.…